Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsJ. Clin. Oncol 2020 Jun 03;[EPub Ahead of Print], A Gul, TF Stewart, CM Mantia, NJ Shah, ES Gatof, Y Long, KD Allman, MC Ornstein, HJ Hammers, DF McDermott, MB Atkins, M Hurwitz, BI Rini
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.